206 related articles for article (PubMed ID: 21826673)
41. Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma.
Jovanovic L; Delahunt B; McIver B; Eberhardt NL; Bhattacharya A; Lea R; Grebe SK
Pathology; 2010; 42(6):524-33. PubMed ID: 20854070
[TBL] [Abstract][Full Text] [Related]
42. Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma.
Prazeres HJ; Rodrigues F; Soares P; Naidenov P; Figueiredo P; Campos B; Lacerda M; Martins TC
Fam Cancer; 2008; 7(2):141-9. PubMed ID: 17823852
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancer.
Bougatef K; Ouerhani S; Moussa A; Kourda N; Coulet F; Colas C; Lahely YB; Najjar T; Ben Jilani S; Benammar-Elgaaied A; Soubrier F; Marrakchi R
Cancer Genet Cytogenet; 2008 Nov; 187(1):12-8. PubMed ID: 18992635
[TBL] [Abstract][Full Text] [Related]
44. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
45. Rapid detection of K-, N-, H-RAS, and BRAF hotspot mutations in thyroid cancer using the multiplex primer extension.
Chang YS; Lin IL; Yeh KT; Chang JG
Clin Biochem; 2013 Oct; 46(15):1572-7. PubMed ID: 23792105
[TBL] [Abstract][Full Text] [Related]
46. Familial nonmedullary thyroid cancer: a review of the genetics.
Khan A; Smellie J; Nutting C; Harrington K; Newbold K
Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534
[TBL] [Abstract][Full Text] [Related]
47. Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.
McKay JD; Thompson D; Lesueur F; Stankov K; Pastore A; Watfah C; Strolz S; Riccabona G; Moncayo R; Romeo G; Goldgar DE
J Med Genet; 2004 Jun; 41(6):407-12. PubMed ID: 15173224
[TBL] [Abstract][Full Text] [Related]
48.
Landriscina M; Natalicchio MI; Lamacchia O; Conserva A; Piscazzi A; Ciampolillo A; Zingrillo M; Pennella A; Bufo P; Vita G; Antonetti R; Maiorano E; Giorgino F; Cignarelli M
Oncol Lett; 2015 Sep; 10(3):1875-1881. PubMed ID: 26622768
[TBL] [Abstract][Full Text] [Related]
49. BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules.
Krohn K; Paschke R
Thyroid; 2004 May; 14(5):359-61. PubMed ID: 15186612
[TBL] [Abstract][Full Text] [Related]
50. Familial nonmedullary thyroid carcinoma.
Mazeh H; Sippel RS
Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of genetic mutations in thyroid cancer: a meta-analysis.
Pak K; Suh S; Kim SJ; Kim IJ
Thyroid; 2015 Jan; 25(1):63-70. PubMed ID: 25244593
[TBL] [Abstract][Full Text] [Related]
52. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
54. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
[TBL] [Abstract][Full Text] [Related]
55. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease.
Mazeh H; Benavidez J; Poehls JL; Youngwirth L; Chen H; Sippel RS
Thyroid; 2012 Jan; 22(1):3-8. PubMed ID: 22136209
[TBL] [Abstract][Full Text] [Related]
56. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile.
De Oliveira Duarte Achcar R; Nikiforova MN; Yousem SA
Am J Clin Pathol; 2009 May; 131(5):694-700. PubMed ID: 19369630
[TBL] [Abstract][Full Text] [Related]
57. BRAF mutations in non-Hodgkin's lymphoma.
Lee JW; Yoo NJ; Soung YH; Kim HS; Park WS; Kim SY; Lee JH; Park JY; Cho YG; Kim CJ; Ko YH; Kim SH; Nam SW; Lee JY; Lee SH
Br J Cancer; 2003 Nov; 89(10):1958-60. PubMed ID: 14612909
[TBL] [Abstract][Full Text] [Related]
58. [Genetic abnormality in thyroid cancers].
Yamashita S
Nihon Rinsho; 2005 Oct; 63 Suppl 10():159-62. PubMed ID: 16279621
[No Abstract] [Full Text] [Related]
59. A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1.
Bevan S; Pal T; Greenberg CR; Green H; Wixey J; Bignell G; Narod SA; Foulkes WD; Stratton MR; Houlston RS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3701-4. PubMed ID: 11502798
[TBL] [Abstract][Full Text] [Related]
60. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
